Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
61 hedge funds and large institutions have $12.5M invested in Zynerba Pharmaceuticals, Inc in 2019 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 13 closing their positions.
55% more capital invested
Capital invested by funds: $8.05M → $12.5M (+$4.45M)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
2% less funds holding
Funds holding: 62 → 61 (-1)
44% less call options, than puts
Call options by funds: $1.16M | Put options by funds: $2.09M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.34M |
| 2 |
Morgan Stanley
New York
|
+$453K |
| 3 |
SC
Sculptor Capital
New York
|
+$436K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$343K |
| 5 |
PP
PDT Partners
New York
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$830K |
| 2 |
Renaissance Technologies
New York
|
-$547K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$545K |
| 4 |
JP Morgan Chase
New York
|
-$427K |
| 5 |
SIM
Spark Investment Management
New York
|
-$369K |
ZYNE Hedge Fund Activity: Q1 2019 in Review
61 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q1 2019, worth a combined $12.5M — up 55% from $8.05M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ZYNE and 12 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 17 added.
The largest buyer was Vanguard Group, adding an estimated $1.34M. The largest seller was Deutsche Bank, exiting entirely with an estimated $830K sold.
- 61 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q1 2019, down from 62 in Q4 2018.
- Funds reported $12.5M of Zynerba Pharmaceuticals, Inc stock for Q1 2019, up 55% quarter-over-quarter.
- 12 funds opened new Zynerba Pharmaceuticals, Inc positions in Q1 2019 and 13 closed out, a net change of -1 holder.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q1 2019 was Vanguard Group, an estimated $1.34M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q1 2019 was Deutsche Bank, an estimated $830K sold.
Based on aggregated 13F filings for Q1 2019.